|
🐜
|
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
16 auth.
S. Buchbinder,
D. Mehrotra,
A. Duerr,
D. Fitzgerald,
R. Mogg,
David Li,
P. Gilbert,
J. Lama,
M. Marmor,
C. del Rio,
...
M. McElrath,
D. Casimiro,
K. Gottesdiener,
J. Chodakewitz,
L. Corey,
Michael N. Robertson
|
10 |
2008 |
10
🐜
|
|
🐜
|
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
21 auth.
M. McElrath,
M. McElrath,
S. C. Rosa,
S. C. Rosa,
Z. Moodie,
S. Dubey,
L. Kierstead,
H. Janes,
O. Defawe,
D. Carter,
...
J. Hural,
Rama S. Akondy,
S. Buchbinder,
Michael N. Robertson,
D. Mehrotra,
Steven G. Self,
S. Self,
L. Corey,
Lawrence Corey,
J. Shiver,
D. Casimiro
|
9 |
2008 |
9
🐜
|
|
🐜
|
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
22 auth.
F. Priddy,
Deborah D. Brown,
J. Kublin,
K. Monahan,
David P Wright,
J. Lalezari,
S. Santiago,
M. Marmor,
Michelle A. Lally,
R. Novak,
...
S. Brown,
P. Kulkarni,
S. Dubey,
L. Kierstead,
D. Casimiro,
R. Mogg,
M. Dinubile,
J. Shiver,
R. Leavitt,
M. Robertson,
D. Mehrotra,
E. Quirk
|
8 |
2008 |
8
🐜
|
|
🐢
|
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?
G. Liu,
K. Lu,
R. Mogg,
M. Mallick,
D. Mehrotra
|
7 |
2009 |
7
🐢
|
|
🐜
|
Scientific white paper on concentration-QTc modeling
11 auth.
C. Garnett,
P. Bonate,
Q. Dang,
G. Ferber,
D. Huang,
Jiang Liu,
...
D. Mehrotra,
S. Riley,
P. Sager,
C. Tornøe,
Yaning Wang
|
7 |
2017 |
7
🐜
|
|
🦁
|
Use of the false discovery rate for evaluating clinical safety data
D. Mehrotra,
J. Heyse
|
6 |
2004 |
6
🦁
|
|
🦁
|
A Cautionary Note on Exact Unconditional Inference for a Difference between Two Independent Binomial Proportions
D. Mehrotra,
I. S. Chan,
R. Berger
|
6 |
2003 |
6
🦁
|
|
🐜
|
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
13 auth.
R. Schooley,
J. Spritzler,
Hongying Wang,
M. Lederman,
D. Havlir,
D. Kuritzkes,
R. Pollard,
Catherine A Battaglia,
M. Robertson,
D. Mehrotra,
...
D. Casimiro,
K. Cox,
B. Schock
|
6 |
2010 |
6
🐜
|
|
🐜
|
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team
17 auth.
Brenda J. Crowe,
H. A. Xia,
J. Berlin,
D. Watson,
Hongliang Shi,
Stephen L Lin,
Juergen Kuebler,
R. Schriver,
N. Santanello,
George Rochester,
...
Jane B Porter,
Manfred Oster,
D. Mehrotra,
Zhengqing Li,
Eileen C King,
E. Harpur,
D. Hall
|
6 |
2009 |
6
🐜
|
|
🐜
|
Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay
19 auth.
S. Dubey,
J. Clair,
T. Fu,
L. Guan,
Romnie Long,
R. Mogg,
K. Anderson,
K. Collins,
C. Gaunt,
V. R. Fernandez,
...
Lan Zhu,
L. Kierstead,
Scott Thaler,
Swati Gupta,
W. Straus,
D. Mehrotra,
T. Tobery,
D. Casimiro,
J. Shiver
|
6 |
2007 |
6
🐜
|
|
🦁
|
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
28 auth.
D. Mehrotra,
H. Janes,
T. Fleming,
P. Annunziato,
K. Neuzil,
Lindsay N. Carpp,
David C. Benkeser,
E. Brown,
M. Carone,
I. Cho,
Deborah Donnell,
M. Fay,
Y. Fong,
Shu Han,
I. Hirsch,
...
Ying Huang,
Yunda Huang,
O. Hyrien,
M. Juraska,
Alexander Luedtke,
M. Nason,
A. Vandebosch,
Honghong Zhou,
M. Cohen,
L. Corey,
J. Hartzel,
D. Follmann,
P. Gilbert
|
6 |
2020 |
6
🦁
|
